Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

A user is experiencing hair loss in the center of their hairline and has been using topical finasteride for seven months with minimal progress. They are considering switching treatments due to concerns about losing ground and potential side effects of other options.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

A user shared a 7-month hair loss treatment progress using finasteride 1.25 mg, oral minoxidil 2.5 mg, ketoconazole shampoo, and monthly micro-needling, noting denser hair and improved quality but no significant regrowth. They experienced mild testicular discomfort and heart palpitations, considering switching to topical minoxidil to avoid side effects.

The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Comparing the effectiveness of minoxidil 5% and adenosine 0.75% for treating male androgenetic alopecia, and measuring patient satisfaction rate; results showed that adenosine is comparable to minoxidil but provides quicker results, however availability of products with adenosine is much less than those with minoxidil.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

Akkermansia bacteria can improve hair growth inhibited by testosterone, and metformin may increase Akkermansia, which could help with hair loss related to aging, insulin resistance, and inflammation.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

An 18-year-old male switched from topical finasteride and minoxidil to oral dutasteride for diffuse hair loss and saw improvement without side effects, despite experiencing scalp itch and shedding. Commenters noted significant hair regrowth and were surprised by his young age and appearance.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

The conversation is about using coenzyme Q10 for hair loss alongside dutasteride. The effectiveness of coenzyme Q10 for treating androgenetic alopecia is questioned due to a lack of evidence.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

The potential accuracy and trustworthiness of websites selling Pyrilutamide, a drug related to hair loss treatments such as Minoxidil, Finasteride, and RU58841; and whether Pyrilutamide is four times stronger than RU58841.

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.